For investors still uncertain about the euro zone's prospects, analysts say there is a safer way to play its nascent recovery: Buy shares of U.S. companies that do a lot of business there.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
The delay of Obamacare's employer mandate isn't a blow to health-care stocks. However, the outlook for reform is another matter.
“The price action is confounding more people than I have seen in some time,” said Cramer. What's going on?
Following are 5 themes and related stock ideas that Jim Cramer likes right here and right now.
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Take a look at some of Monday's midday movers:
One biotech name has the best upside potential for 2013, pharmaceutical analyst Barbara Ryan says.
If you're young and not buying stocks, Cramer thinks you'll regret it.
Pockets of weakness in the market have captured Cramer's attention. Is the selling really warranted?
Check out which companies are making headlines after the bell Monday:
It's make-or-break time for the first-quarter earnings season, and it comes just as the stock market is showing signs of strain.
It seems like that historic high for the S&P 500 was 5 years ago, but it's not. We're only 3.5 percent off the historic high in the S&P 500, which occurred exactly one week ago.
The commodity markets have reached a key turning point, and U.S. equities will reap the benefits, Jim Cramer says.
Deflationary winds? Traders are fixing on the idea of deflationary fears as the main reason commodities and commodity stocks are down so much.
Some cancers could be cured within the next couple of years, Celgene CEO Robert Hugin told CNBC.
Some of the names on the move ahead of the open.
Take a look at some of Thursday's midday movers:
Share price may already seem high but Jim Cramer thinks it deserves to be even higher.